Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases

Emerging as a paradigm-shifting therapeutic strategy initially developed for hematological malignancies, chimeric antigen receptor (CAR)-based cell therapy has recently proved transformative potential in autoimmune disease management. CAR T cell therapy has achieved long-term remission without drugs...

Full description

Saved in:
Bibliographic Details
Main Authors: Mingwei Jiang, Jin Zhao, Jinguo Yuan, Zixian Yu, Jie Liu, Zhanxin Zhu, Xiaoxuan Ning, Shiren Sun
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2538350
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849706059484102656
author Mingwei Jiang
Jin Zhao
Jinguo Yuan
Zixian Yu
Jie Liu
Zhanxin Zhu
Xiaoxuan Ning
Shiren Sun
author_facet Mingwei Jiang
Jin Zhao
Jinguo Yuan
Zixian Yu
Jie Liu
Zhanxin Zhu
Xiaoxuan Ning
Shiren Sun
author_sort Mingwei Jiang
collection DOAJ
description Emerging as a paradigm-shifting therapeutic strategy initially developed for hematological malignancies, chimeric antigen receptor (CAR)-based cell therapy has recently proved transformative potential in autoimmune disease management. CAR T cell therapy has achieved long-term remission without drugs in a variety of autoimmune diseases. Chimeric autoantigen receptor T cell therapy targeting specific B cell receptors has transitioned from preclinical research to clinical trials. CAR natural killer cell therapy has shown promising efficacy and safety in early-stage clinical trials. The evolution of CAR regulatory T cell and mesenchymal stem cell therapy has also achieved initial results. These achievements have greatly inspired researchers, and more research is being actively carried out in the field of autoimmune diseases, aiming to develop more efficient, safe and convenient cell products. This article will detail the effectiveness and applicability of CAR-based immunotherapy in the management of autoimmune diseases, and explore its limitations and future trends.
format Article
id doaj-art-cb48b33bedd8420aa92c1d9ac38244bb
institution DOAJ
issn 2164-5515
2164-554X
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj-art-cb48b33bedd8420aa92c1d9ac38244bb2025-08-20T03:16:18ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2538350Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseasesMingwei Jiang0Jin Zhao1Jinguo Yuan2Zixian Yu3Jie Liu4Zhanxin Zhu5Xiaoxuan Ning6Shiren Sun7Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, Shaanxi Provincial Clinical Research Center for Kidney Diseases, Xi’an, Shaanxi, ChinaDepartment of Nephrology, Xijing Hospital, The Fourth Military Medical University, Shaanxi Provincial Clinical Research Center for Kidney Diseases, Xi’an, Shaanxi, ChinaDepartment of Nephrology, Xijing Hospital, The Fourth Military Medical University, Shaanxi Provincial Clinical Research Center for Kidney Diseases, Xi’an, Shaanxi, ChinaDepartment of Nephrology, Xijing Hospital, The Fourth Military Medical University, Shaanxi Provincial Clinical Research Center for Kidney Diseases, Xi’an, Shaanxi, ChinaDepartment of Nephrology, Xijing Hospital, The Fourth Military Medical University, Shaanxi Provincial Clinical Research Center for Kidney Diseases, Xi’an, Shaanxi, ChinaDepartment of Nephrology, Xijing Hospital, The Fourth Military Medical University, Shaanxi Provincial Clinical Research Center for Kidney Diseases, Xi’an, Shaanxi, ChinaDepartment of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, ChinaDepartment of Nephrology, Xijing Hospital, The Fourth Military Medical University, Shaanxi Provincial Clinical Research Center for Kidney Diseases, Xi’an, Shaanxi, ChinaEmerging as a paradigm-shifting therapeutic strategy initially developed for hematological malignancies, chimeric antigen receptor (CAR)-based cell therapy has recently proved transformative potential in autoimmune disease management. CAR T cell therapy has achieved long-term remission without drugs in a variety of autoimmune diseases. Chimeric autoantigen receptor T cell therapy targeting specific B cell receptors has transitioned from preclinical research to clinical trials. CAR natural killer cell therapy has shown promising efficacy and safety in early-stage clinical trials. The evolution of CAR regulatory T cell and mesenchymal stem cell therapy has also achieved initial results. These achievements have greatly inspired researchers, and more research is being actively carried out in the field of autoimmune diseases, aiming to develop more efficient, safe and convenient cell products. This article will detail the effectiveness and applicability of CAR-based immunotherapy in the management of autoimmune diseases, and explore its limitations and future trends.https://www.tandfonline.com/doi/10.1080/21645515.2025.2538350Autoimmune diseaseschimeric antigen receptorsCAR TCAR NKCAR tregimmunotherapy
spellingShingle Mingwei Jiang
Jin Zhao
Jinguo Yuan
Zixian Yu
Jie Liu
Zhanxin Zhu
Xiaoxuan Ning
Shiren Sun
Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
Human Vaccines & Immunotherapeutics
Autoimmune diseases
chimeric antigen receptors
CAR T
CAR NK
CAR treg
immunotherapy
title Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
title_full Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
title_fullStr Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
title_full_unstemmed Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
title_short Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
title_sort research progress on chimeric antigen receptor based immunotherapy against autoimmune diseases
topic Autoimmune diseases
chimeric antigen receptors
CAR T
CAR NK
CAR treg
immunotherapy
url https://www.tandfonline.com/doi/10.1080/21645515.2025.2538350
work_keys_str_mv AT mingweijiang researchprogressonchimericantigenreceptorbasedimmunotherapyagainstautoimmunediseases
AT jinzhao researchprogressonchimericantigenreceptorbasedimmunotherapyagainstautoimmunediseases
AT jinguoyuan researchprogressonchimericantigenreceptorbasedimmunotherapyagainstautoimmunediseases
AT zixianyu researchprogressonchimericantigenreceptorbasedimmunotherapyagainstautoimmunediseases
AT jieliu researchprogressonchimericantigenreceptorbasedimmunotherapyagainstautoimmunediseases
AT zhanxinzhu researchprogressonchimericantigenreceptorbasedimmunotherapyagainstautoimmunediseases
AT xiaoxuanning researchprogressonchimericantigenreceptorbasedimmunotherapyagainstautoimmunediseases
AT shirensun researchprogressonchimericantigenreceptorbasedimmunotherapyagainstautoimmunediseases